New chemo cocktail shows promise against aggressive childhood cancer
NCT ID NCT00077285
First seen Nov 04, 2025 · Last updated May 08, 2026 · Updated 21 times
Summary
This study tested a combination of two chemotherapy drugs, irinotecan and carboplatin, as the first treatment for people newly diagnosed with intermediate- or high-risk rhabdomyosarcoma, a type of muscle cancer. The goal was to see if this drug pair could shrink tumors and be safe. The trial included 65 participants and focused on how well the cancer responded and any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.